PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 24, 2025JACC Asia3 citationsOpen Access

Effect of Body Mass Index in Patients With Cardiogenic Shock Requiring Microaxial Flow Pump

YKYuki KatagiriYKYutaro KasaiMMMamoru Miyazaki

Key Result

Obesity (HR 1.37; 95% CI 1.19-1.57; P<0.001) and severe obesity (HR 2.00; P<0.001) were associated with increased 30-day mortality in cardiogenic shock patients treated with microaxial flow pumps.

Study Design

Type

Observational

Structured PICO

Does body mass index affect 30-day mortality in patients with cardiogenic shock treated with microaxial flow pumps?

P
Population
3,636 consecutive patients with cardiogenic shock (CS) treated with microaxial flow pumps (mAFP) between February 2020 and December 2022, median age 69.0, 22.2% female, from the Japanese nationwide J-PVAD registry. Exclusion criteria: <20 years old, postcardiotomy CS, unsuccessful mAFP delivery, or missing BMI/outcome data.
I
Intervention
Body mass index (BMI) categories: underweight (<18.5 kg/m2), overweight (23.0-24.9 kg/m2), obesity (25.0-29.9 kg/m2), and severe obesity (≥30.0 kg/m2) in patients receiving microaxial flow pump (mAFP) therapy.
C
Comparator
Normal weight (BMI 18.5-22.9 kg/m2) group receiving microaxial flow pump (mAFP) therapy.
O
Outcome
30-day all-cause mortalityhard clinical

In patients with cardiogenic shock treated with microaxial flow pumps, higher BMI is independently associated with increased 30-day mortality, contrasting with the obesity paradox observed in other cardiovascular conditions.

Main Result

Effect estimate: HR 1.37 (95% CI 1.19-1.57)

p-value: p=< 0.001

Limitations

  • Limited number of observations in subgroup analysis
  • Retrospective nature of the analysis

Abstract

BACKGROUND: The impact of obesity on mortality in patients with cardiogenic shock (CS) requiring microaxial flow pumps (mAFP) remains undetermined. OBJECTIVES: This study investigated the effect of body mass index (BMI) on mortality in CS patients treated with mAFP. METHODS: ). Multivariate Cox regression analysis assessed the relationship between BMI and 30-day mortality. RESULTS: Crude 30-day mortality increased incrementally with higher BMI categories. Adjusted HRs for 30-day mortality (normal weight as reference) were 0.71 (95% CI CI: 0.56-0.90; P = 0.005) for underweight, 1.03 (95% CI: 0.88-1.21; P = 0.681) for overweight, 1.37 (95% CI: 1.19-1.57; P < 0.001) for obesity, and 2.00 (95% CI: 1.66-2.41; P < 0.001) for severe obesity. Patients in the underweight and severe obesity groups experienced a higher incidence of bleeding after percutaneous coronary intervention under mAFP, whereas hemolysis increased with higher BMI categories. Bleeding and hemolysis were associated with mortality only in patients who were underweight. CONCLUSIONS: Higher BMI was associated with increased mortality in CS patients treated with mAFP. Although patients who were underweight demonstrated overall favorable survival outcomes, bleeding and hemolysis contributed to mortality in this group. Further research is needed to explore whether a BMI-based approach can improve clinical outcomes. (Japanese registry for Percutaneous Ventricular Assist Device; UMIN000033603).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Katagiri et al. (2025) conducted an observational in Cardiogenic shock requiring microaxial flow pump. Higher BMI categories (obesity and severe obesity) vs. Normal weight was evaluated on 30-day mortality (HR 1.37, 95% CI 1.19-1.57, p=< 0.001). Obesity (HR 1.37; 95% CI 1.19-1.57; P<0.001) and severe obesity (HR 2.00; P<0.001) were associated with increased 30-day mortality in cardiogenic shock patients treated with microaxial flow pumps.

synapsesocial.com/papers/6a085b039a6c4ba6e610951ahttps://doi.org/10.1016/j.jacasi.2025.03.003
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock2012 · 2,844 citations
  2. 2Changes in cardiac output, rhythm regularity, and symptom severity after electrical cardioversion of atrial fibrillation2023 · 6 citations
  3. 3Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study2017 · 33 citations
  4. 4P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial2023 · 22 citations
  5. 5Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock2024 · 907 citations